Akèy › Kansè ovè › Tennessee › Chattanooga

Etid klinik pou Kansè ovè nan Chattanooga, TN

5 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Chattanooga (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Ap rekriteFaz 3

Erlanger Health, Chattanooga

Laj 18 ak plis · Fanm · Mizajou Oct 5, 2026 · NCT06915025

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Ap rekriteFaz 3

Erlanger Health, Inc., Chattanooga

Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT07214779

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Ap rekriteFaz 3

Erlanger Health, Inc., Chattanooga

Laj 18 ak plis · Fanm · Mizajou Aug 26, 2026 · NCT05281471

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Ap rekriteFaz 1/2

Erlanger Health, Inc, Chattanooga

Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Ap rekriteFaz 1/2

Tennessee Oncology, PLLC, Chattanooga

Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068

Etid Kansè ovè nan lòt vil

Lòt etid nan Chattanooga

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.